BOSTON – Tapering but perhaps not completely stopping tumor necrosis factor inhibitors can result in good control of rheumatoid arthritis with considerable cost savings, according to investigators in...
BOSTON – A nonsteroidal investigational drug that acts on the glucocorticoid receptor was superior to placebo and noninferior to higher-dose prednisone in adults with rheumatoid arthritis,...
BOSTON – Golimumab was significantly better than placebo at reducing disease activity and inflammation in patients with nonradiographic axial spondyloarthritis, but only among those who were positive...
BOSTON– In the search for safer alternatives to glucocorticoid therapy, DAGR (PF-0417327) may prove to be a contender. The investigational drug is a selective, high-affinity, dissociated agonist of...
BOSTON – It took 10 years to find out that mycophenolate mofetil and azathioprine are comparable as maintenance therapies for patients with lupus nephritis, at least in a European population.
Or as...
BOSTON – Low expression of protein A20 in minor salivary gland tissue appears to be associated with lymphomas in patients with primary Sjögren’s syndrome.
In an interview after his late-breaker...
BOSTON – Low expression of protein A20 in minor salivary gland tissue appears to be associated with lymphomas in patients with primary Sjögren’s syndrome.
In an interview after his late-breaker...
BOSTON – Two investigational monoclonal antibodies, each targeting a different cytokine, showed good activity against systemic lupus erythematosus in two separate studies presented at the annual...
BOSTON – Secukinumab showed enduring efficacy in ankylosing spondylitis after 52 weeks of treatment, based on data reported at the annual meeting of the American College of Rheumatology.
The...
BOSTON – Nearly all hospitalizations of people who were discharged with a primary diagnosis of gout were likely preventable, based on the results of a retrospective analysis of 79 cases at a single...